Beijing Beilu Pharmaceutical (300016.SZ) obtained the registration certificate for the drug Pioglitazone Metformin Tablets.

Beilu Pharmaceutical (300016.SZ) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for pioglitazone metformin tablets (15mg/500mg). This product is suitable for type 2 diabetes patients who are currently being treated with pioglitazone hydrochloride and metformin hydrochloride in combination on the basis of diet control and exercise, or for type 2 diabetes patients whose blood sugar control is not satisfactory after treatment with metformin hydrochloride alone.